orladeyo®

(berotralstat) capsules 150 mg
oral pellets 72•96•108•132 mg

A CLINICAL LOOK AT ORLADEYO: FROM RESULTS TO REAL-WORLD PRACTICE

Sponsored by BioCryst Pharmaceuticals, Inc.

Breakfast will be offered.

This program/event is developed and offered by BioCryst Pharmaceuticals.
This is not an official program/event of the Cleveland Clinic.

Capsule
12+ years old



Oral pellets
2 to <12 years old

Capsule and pellets not actual size.
Refer to Prescribing Information for the recommended daily dose for patients 2 to <12 years of age.

Letty, 8, prescribed ORLADEYO in 2026

SPEAKER

Daniel Soteres, MD, MPH
Asthma & Allergy Associates, PC and Research Center
Colorado Springs, CO

PATIENT AMBASSADOR

Kelly, started ORLADEYO in 2021

DATE & TIME

Saturday, September 19, 2026
7:15 AM ET

LOCATION

Non-CME Satellite in Six Continents Room

For US healthcare professionals only. This program is not certified for continuing education credit.

INDICATION

ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.

Limitations of use

The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation.

IMPORTANT SAFETY INFORMATION

An increase in QTc interval was observed in adults at dosages higher than 150 mg once daily and was concentration dependent.

The most common adverse reactions (≥10%) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

In adult and pediatric patients aged 12 years and older with moderate or severe hepatic impairment (Child-Pugh B or C), the recommended dosage of ORLADEYO capsules is 110 mg once daily with food. In pediatric patients aged 2 to <12 years with moderate or severe hepatic impairment (Child-Pugh B or C), avoid use of ORLADEYO.

Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use of P-gp inducers with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. Concomitant use of ORLADEYO with CYP2D6 or CYP3A4 substrates can increase exposure of the CYP2D6 or CYP3A4 substrates and may increase the risk of adverse reactions associated with the substrates. If ORLADEYO is concomitantly used with CYP2D6 or CYP3A4 substrates where minimal increases in the concentration of the substrates may lead to serious adverse reactions, closely monitor or modify the dosage of the CYP2D6 or CYP3A4 substrate.

The safety and effectiveness of ORLADEYO in pediatric patients <2 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information available at this meeting.

To access state-required price disclosures for ORLADEYO, visit www.biocryst.com/company/about-us or scan the code.